CD79a antibody (AA 202-216)
Quick Overview for CD79a antibody (AA 202-216) (ABIN3024106)
Target
See all CD79a (CD79A) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 202-216
-
Purification
- Protein G affinity chromatography
-
Immunogen
- A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79a protein (JCB117 and HM47/A9) was used as the immunogen for this antibody cocktail.
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. FACS: 0.5-1 μg/million cells,IF: 0.5-1 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1),Prediluted format : incubate for 30 min at RT (2) -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the CD79a antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
-
Alternative Name
- CD79a
-
Background
- A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
-
Gene ID
- 973
-
Pathways
- BCR Signaling
Target
-